British Journal of Haematology

Article	Citations
e‐Posters	144
CAR T in patients with large B‐cell lymphoma not fit for autologous transplant	119
Graham Serjeant, Sickle Cell, Jamaica and Beyond: A Life, Ian Randle Publishers (Kingston and Miami), 2021	114
Functional impairment of erythropoiesis in Congenital Dyserythropoietic Anaemia type I arises at the progenitor level	87
Guideline for the diagnosis and management of marginal zone lymphomas: A British Society of Haematology Guideline	84
COSMIC, chemotherapy plus ofatumumab at standard or mega‐dose in chronic lymphocytic leukaemia, a phase II randomised study	81
A novel MYC–non‐IG fusion in refractory diffuse large B‐cell lymphoma	75
Alternative donor transplantation for severe aplastic anaemia in 2021: haplo donor, cord blood or both?	74
Myelodysplastic syndrome associated‐haemophagocytic lymphohistiocytosis: A retrospective study of 15 cases in a single centre	73
Issue Information	73
	71
Don't forget cord blood in non‐remission acute myeloid leukaemia!	70
Venous thromboembolism incidence associated with pegylated asparaginase (ASP) compared to the native L‐ASP: A retrospective analysis with an ASP‐based protocol in adult patients with acute lympho	65
Issue Information	62
Late recurrence of lymphoid malignancies after initial treatment for Hodgkin lymphoma – A study from the Danish Lymphoma Registry	59
Erythrophagocytosis in a patient with myelodysplastic syndrome with excess blasts‐1 with isolated del(6q)	58
Use of dipyridamole is associated with lower risk of lymphoid neoplasms: a propensity score‐matched cohort study	54
Issue Information	53
Whole‐exome sequencing uncovered genetic diagnosis of severe inherited haemolytic anaemia: Correlation with clinical phenotypes	52
Population‐based cohort study of the efficacy of brentuximab vedotin in relapsed systemic anaplastic large‐cell lymphoma using Public Health England data	52
Stratified management based on surface antibody for the prevention of hepatitis B virus reactivation in lymphoma patients	50
Applying current smouldering myeloma risk models to a UK single‐centre cohort and clinical features at progression	50
Obinutuzumab as consolidation after chemo‐immunotherapy: Results of the UK National Cancer Research Institute phase II/III GALACTIC trial	50
Correction to “Cytidine deaminase status as a marker of response to azacytidine treatment in MDS and AML patients”	48
Association of biomarkers of endothelial function, coagulation activation and kidney injury with persistent albuminuria in sickle cell anaemia	48

Management of immunosuppression in post‐transplant lymphoproliferative disorders treated with CAR T cells	47
A 4‐gene prognostic index for enhancing acute myeloid leukaemia survival prediction	46
Immunophenotypic clustering in paediatric acute myeloid leukaemia	46
Management of luspatercept therapy in patients with transfusion‐dependent β‐thalassaemia	45
ATG versus PTCy in matched unrelated donor haematopoietic stem cell transplantations with non‐myeloablative conditioning	44
Venetoclax ramp‐up strategies for chronic lymphocytic leukaemia in the United Kingdom: a real world multicentre retrospective study	43
Characterisation of two tumour cell populations in the small cell variant of anaplastic lymphoma kinase‐positive anaplastic large cell lymphoma	42
The impact of COVID‐19 vaccination on patients with a history of heparin‐induced thrombocytopenia	41
Hepatic haemophagocytosis in haematology patients with hepatic dysfunction: prognostic impact and contribution of liver biopsy combined with the haemophagocytic syndrome diagnostic score (HScore)	40
	39
Issue Information	38
Does eventually NPM1 mutation in blast phase chronic myeloid leukemia (BP‐CML) exist? That is the question.	38
Non‐pharmacological supportive‐care interventions in acute myeloid leukaemia: a review of randomised controlled trials	37
The oldest case of lymphoma? Insights from a XIII century fresco	37
Indirect presentation of mismatched human leukocyte antigen‐B associates with outcomes of cord blood transplantation	37
Antibody response to a third SARS‐CoV‐2 vaccine dose in recipients of an allogeneic haematopoietic cell transplantation	36
The role of genetics in refractory immune thrombocytopenia	35
Liquid biopsy in Hodgkin lymphoma – moving beyond the proof of principle	35
Patient preferences in the treatment of stage III/IV classic Hodgkin lymphoma: Results from the CONNECT cross‐sectional survey	34
The significance of mixed chimaerism and cell lineage chimaerism monitoring in paediatric patients post haematopoietic stem cell transplant	34
How I manage myeloproliferative neoplasm‐unclassifiable: Practical approaches for 2022 and beyond	33
Phase Ib study of eltrombopag and azacitidine in patients with high‐risk myelodysplastic syndromes and related disorders (the ELASTIC study)	33
Transcriptional and genomic characterization of measurable residual disease in acute myeloid leukaemia	33
Positron emission tomography derived metrics in relapsed or refractory large B‐cell lymphoma with residual disease before autologous stem cell transplant	31
Clinical perspectives on post‐induction maintenance therapy in patients with acute myeloid leukaemia in remission who are ineligible for allogeneic haematopoietic stem cell transplantation	31
Full chimaeric CAR.CIK from patients engrafted after allogeneic haematopoietic cell transplant: Feasibility, anti‐leukaemic potential and alloreactivity across major human leukoc	30
Empagliflozin modulates CD4+ T‐cell differentiation via metabolic reprogramming in immune thrombocytopenia	29
A phase II study of ibrutinib in combination with ixazomib in patients with Waldenström macroglobulinaemia	29
Immune thrombocytopenic purpura after SARS‐CoV‐2 vaccine	29
Concomitant HIV‐associated plasmablastic lymphoma and visceral leishmaniasis at initial presentation	28
Lower anti‐spike levels in B‐cell‐depleted patients after convalescent plasma transfusion suggest the need for repeated doses	28
Long‐term outcome after allogeneic stem cell transplantation for GATA2 deficiency: An analysis of 67 adults and children from France and Belgium	28
Immune thrombocytopenia (ITP) in pregnancy	28
Efficacy and safety of heterologous booster vaccination with Ad26.COV2.S after BNT162b2 mRNA COVID‐19 vaccine in haemato‐oncological patients with no antibody response	28
Would you like to take some more ruxolitinib after your fedratinib?	28
Haematopoietic stem cell mobilisation followed by high‐dose chemotherapy and autologous stem cell transplantation for patients with sickle cell disease and myeloma	28
A safety and efficacy study of allogeneic haematopoietic stem cell transplantation for refractory and relapsed T‐cell acute lymphoblastic leukaemia/lymphoblastic lymphoma patients who achieved complet	27
Inhibition of the Sec61 translocon overcomes cytokine‐induced glucocorticoid resistance in T‐cell acute lymphoblastic leukaemia	27
Evaluating the impact of thrombopoietin receptor agonist medications on patient outcomes and quality of life in paediatric immune thrombocytopenia through semi‐structured interviews	27
How to dose and monitor argatroban for treatment of HIT	27
MYC‐induced cytidine metabolism regulates survival and drug resistance via cGas‐STING pathway in mantle cell lymphoma	27
Quality of life in childhood immune thrombocytopenia: Revision of the Kids' ITP Tools (KIT)	27
Prolonged platelet hyperactivity after COVID‐19 infection	27
SOCS3 deregulation contributes to aberrant activation of the JAK/STAT pathway in precursor T‐cell neoplasms	26
Identification and management of preoperative anaemia in adults: A British Society for Haematology Guideline update	26
R‐CHOP treatment for patients with advanced follicular lymphoma: Over 15‐year follow‐up of JCOG0203	26
Immune‐mediated thrombocytopenia and IL‐6‐mediated thrombocytosis observed in idiopathic multicentric Castleman disease	26
Guidelines for the diagnosis and management of adult aplastic anaemia: A British Society for Haematology Guideline	25
Allogeneic haematopoietic cell transplant in patients with relapsed/refractory anaplastic large cell lymphoma—Response	25
Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase‐2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts	25

Issue Information	25
Using the in vitro drug sensitivity test to identify candidate treatments for transient abnormal myelopoiesis	25
Acute myeloid leukaemia with SRSF2 and BRAF mutations preceded by histiocytic proliferation in the bone marrow	25
A CD38/CD3xCD28 trispecific T‐cell engager as a potentially active agent in multiple myeloma patients relapsed and/or refractory to anti‐CD38 monoclonal antibodies	24
A rare case of transformation from relapsed acute monocytic leukaemia with KMT2A::MLLT10 to acute megakaryoblastic leukaemia	24
Acute megakaryoblastic leukaemia with erythrophagocytosis	24
The effect of antinuclear antibody titre and its variation on outcomes in children with primary immune thrombocytopenia	23
Hyperammonemia and acute liver failure associated with deferasirox in two adolescents with sickle cell disease	23
A treatment strategy to mitigate the adverse effect of pretransplant mogamulizumab on post‐transplant clinical outcome in patients with aggressive ATL	23
Acute megakaryoblastic leukaemia shows high frequency of chromosome 1q aberrations and dismal outcome	23
Bridging the implementation gap in medication adherence. If you build it, will they come?	23
Comprehensive characterization of a novel, oncogenic and targetable SEPTIN6::ABL2 fusion in T‐ALL	23
	23
Obituary Dr Christine Costello: MBChB, DRCOG, FRCP, FRCPath 29 August 1945–31 December 2021	22
Exploratory study on the individualized application of eltrombopag in paediatric immune thrombocytopenia guided by therapeutic drug monitoring	22
Beware clonal haematopoiesis following chronic lymphocytic leukaemia treatment	22
Evaluation of coverage, generalisability and validity of the U‐CAN lymphoma biobank in Sweden: A comparison with nationwide registers	22
Issue Information	22
Are HPA‐5b antibodies a significant cause of FNAIT and associated bleeding or merely an incidental finding?	22
Factor VII deficiency: A cause of (or risk factor for) bleeding?	21
	21
Issue Information	21
	21
Autoimmune cytopenia and Kabuki syndrome in paediatrics: Insights in 11 patients	20
Antibody response and intra‐host viral evolution after plasma therapy in COVID‐19 patients pre‐exposed or not to B‐cell‐depleting agents	20
Ratio of stemness to interferon signalling as a biomarker and therapeutic target of myeloproliferative neoplasm progression to acute myeloid leukaemia	20
Iron parameters in pregnant women with beta‐thalassaemia minor combined with iron deficiency anaemia compared to pregnant women with iron deficiency anaemia alone demonstrate the safety of iron supple	20
GBT021601 improves red blood cell health and the pathophysiology of sickle cell disease in a murine model	20
Impact of bone marrow involvement on early positron emission tomography response and progression‐free survival in the HD18 trial for patients with advanced‐stage Hodgkin lymphoma	20
Haematopoietic stem cell transplantation after reduced intensity conditioning in children and adolescents with chronic myeloid leukaemia: A prospective multicentre trial of the I‐BFM Study	20
Novel transferrin gene mutations in four new cases of congenital Atransferrinaemia: Functional and diagnostic pathogenicity despite negative bioinformatics	19
A synonymous variant is unmasked in thalassaemia	19
The application of a multidisciplinary approach in the diagnosis of Castleman disease and Castleman‐like lymphadenopathies: A 20‐year retrospective analysis of clinical and pathological features	19
Clinical decision support to reduce unnecessary diagnostic testing for heparin‐induced thrombocytopenia	19
Management of cardiovascular complications of bruton tyrosine kinase inhibitors	19
Ruxolitinib‐based regimen in children with autoimmune disease or autoinflammatory disease‐related haemophagocytic lymphohistiocytosis	19
Blinatumomab differentially modulates peripheral blood and bone marrow immune cell repertoire: A Campus ALL study	19
Association of the Geriatric 8 with treatment intensity and prognosis in older patients with diffuse large B‐cell lymphoma	19
Current status of haemophilia inhibitor management in mainland China: a haemophilia treatment centres survey on treatment preferences and real‐world clinical practices	19
Association of human leucocyte antigen loci with vaccine‐induced immune thrombotic thrombocytopenia: Potential role of the interaction between platelet factor 4‐derived peptides and MHC‐	19
Incidence and impact of community respiratory viral infections in post‐transplant cyclophosphamide‐based graft‐versus‐host disease prophylaxis and haploidentical stem cell transplantation	19
Urinary angiotensinogen is associated with albuminuria in adults with sickle cell anaemia	18
A single dose of eculizumab terminated life‐threatening haemolysis in idiopathic IgM‐mediated warm autoimmune haemolytic anaemia: A case report	18
Outcomes of young adults (aged ≤ 40 years) with newly diagnosed multiple myeloma after up‐front autologous stem cell transplant	18
Another side of IgA neoplastic plasma cells	18
Outcomes of allogeneic or autologous stem cell transplantation followed by maintenance chemotherapy in adult patient with B‐ALL in CR1 with no detectable minimal residual disease	18
Antithrombin III deficiency‐induced coagulopathy in the context of COVID‐19: a case series	18
Time‐to‐event surrogate end‐points in multiple myeloma randomised trials from 2005 to 2019: A surrogacy analysis	18
Risk of infections with bispecific antibodies in B‐cell non‐Hodgkin lymphomas and multiple myeloma—The current state	18
Successful treatment of relapsed idiopathic multicentric Castleman disease–idiopathic plasmacytic lymphadenopathy with orelabrutinib monotherapy: A case report	18
Relevance of the E756del common variant in the PIEZO1 gene for haemolytic anaemia and hepatic iron overload	18
A defined serum‐free culture system for human long‐term haematopoietic stem cells	18
SLN124, a GalNac‐siRNA targeting transmembrane serine protease 6, in combination with deferiprone therapy reduces ineffective erythropoiesis and hepatic iron‐overload in a mouse model of β‐thalassaemi	18
Erratum to: The HMG‐CoA inhibitor, simvastatin, triggers in vitro anti‐tumour effect and decreases IgM secretion in Waldenstrom macroglobulinaemia	18
Recurrence after stopping anticoagulants in women with combined oral contraceptive‐associated venous thromboembolism: A systematic review and meta‐analysis	18
Extended phenotyping does not preclude the occurrence of delayed haemolytic transfusion reactions in sickle cell disease	18
Correction to “Refractory/relapse thrombocytopenia in a patient with Evans' syndrome successfully treated with zanubrutinib”LiM, LiuL, DingB, SongX, XiaA, HanY, et al. Refractory/relapse thrombocytope	18
Hypomethylating agent/venetoclax versus intensive chemotherapy in adults with relapsed or refractory acute myeloid leukaemia	18
Tyrosine kinase inhibitor maintenance following chimeric antigen receptor T‐cell therapy in Philadelphia chromosome‐positive acute lymphoblastic leukaemia	18
Toward a paradigm shift in prognostication and treatment of early‐stage Hodgkin lymphoma	18
Issue Information	17
Mutation spectrum of FLT3 and significance of non‐canonical FLT3 mutations in haematological malignancy	17
Immature platelets in COVID‐19 infection	17
Proteomic analysis of neutrophils from patients with COVID‐19	17
Extended vincristine and dexamethasone pulse therapy may not be necessary for children with TCF3‐PBX1 positive acute lymphoblastic leukaemia	17
Multiple myeloma with acicular crystalline inclusion bodies	17
	17
Management of children and adults with all stages of nodular lymphocyte predominant Hodgkin lymphoma — All StAGEs: A consensus‐based position paper from the Hodgkin lymphoma subgroup	17
The UK SPIRIT 1 trial in newly diagnosed chronic myeloid leukaemia	17
Safe use of hydroxycarbamide in sickle cell disease patients hospitalized for painful vaso‐occlusive episodes during the randomized, open‐label HELPS study	17
Metformin augments GPRC5D in multiple myeloma and enhances the efficacy of GPRC5D‐CAR T cells	17
Survival prediction optimization of acute myeloid leukaemia based on T‐cell function‐related genes and plasma proteins	17
Acute chest syndrome in adult patients with sickle cell disease: The relationship with the time to onset after hospital admission	17
Resistance to Bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non‐Hodgkin lymphoma	17
Myeloperoxidase creates a permissive microenvironmental niche for the progression of multiple myeloma	17
Treatment with fostamatinib in patients with immune thrombocytopenia: Experience from the Andalusian region in Spain—The Fostasur Study	17
Issue Information	17
Demographic and clinical characteristics of acute myeloid leukaemia diagnosed and treated at the tertiary level in Afghanistan	17
Long‐term real‐world outcomes of patients with acute promyelocytic leukaemia treated with arsenic trioxide and all‐trans retinoic acid without chemotherapy—a retrospective, single‐centre study	16
Biochemical screening of glucose‐6‐phosphate dehydrogenase deficiency in borderline cases: Complementary inputs of standardization enzymes and comparison with genetic status	16

Prognostic impact of pretreatment cell‐free DNA concentration in newly diagnosed peripheral T‐cell lymphomas	16
Haematopoietic stem cell transplantation for severe autoimmune diseases in children: A review of current literature, registry activity and future directions on behalf of the autoimmune diseases and pa	16
t(9;12)(q22;p13) ETV6::SYK: A new recurrent cytogenetic aberration and tyrosine kinase gene fusion in myeloid or lymphoid neoplasms associated with eosinophilia	16
Clinical and neurophysiological aspects of peripheral neuropathy in patients with myelodysplastic syndromes	16
Chemotherapy‐induced thrombocytopenia: modern diagnosis and treatment	16
Reframing thalassaemia syndrome as a benign haematopoietic stem cell disorder	16
Immature platelets as a biomarker for disease severity and mortality in COVID‐19 patients	16
Daratumumab for the management of autoimmune cytopenias in children and young adults: a case series	16
Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study	16
	16
Venetoclax resistance in acute myeloid leukaemia—Clinical and biological insights	16
Idecabtagene vicleucel: questions regarding the appropriate role and cost	16
Update on B‐cell maturation antigen‐directed therapies in AL amyloidosis	16
Up‐regulation of miR‐130a is related to leg ulcers in sickle cell anaemia	16
The impact of biomarkers of malignancy (IMWG SLiM criteria) in myeloma in a real‐world population: Clinical characteristics, therapy and outcomes from the Australian and New Zealand Myeloma	16
Hedgehog blockade in steroid‐refractory sclerotic chronic graft‐versus‐host disease	15
Phase II trial of hypomethylating agent combined with nivolumab for acute myeloid leukaemia relapse after allogeneic haematopoietic cell transplantation—Immune signature correlates with response	15
The distribution and accumulation of the shortest telomeres in telomere biology disorders	15
Chronic refractory immune thrombocytopenia in adolescents and young adults	15
A rare homozygous variant in TERT gene causing variable bone marrow failure, fragility fractures, rib anomalies and extremely short telomere lengths with high serum IgE	15
Outcomes of patients with secondary central nervous system lymphoma treated with chimeric antigen receptor T‐cell therapy: A CIBMTR analysis	15
Predicting therapy‐related myeloid neoplasms after CAR‐T with the Clonal Haematopoiesis Risk Score (CHRS)	15
Temporal trends in relative survival of diffuse large B‐cell lymphoma in Sweden and Denmark in the era of targeted and cellular therapies	15
Clinical significance of mitochondrial DNA content in acute promyelocytic leukaemia	15
Oral decitabine/cedazuridine versus intravenous decitabine for acute myeloid leukaemia: A randomised, crossover, registration, pharmacokinetics study	15
Oral azacitidine modulates the bone marrow microenvironment in patients with acute myeloid leukaemia in remission: A subanalysis from the QUAZAR AML‐001 trial	15
Dimethyl fumarate ameliorates graft‐versus‐host disease by inhibiting T‐cell metabolism and immune responses through a reactive oxygen species‐dependent mechanism	15
Incidence, prevalence and survival in patients with Langerhans cell histiocytosis: A national registry study from England, 2013–2019	15
A two‐part, single‐arm, multicentre, phase I study of zanubrutinib, a selective Bruton tyrosine kinase inhibitor, in Chinese patients with relapsed/refractory B‐cell malignancies	15
Incidence, characteristics and clinical profile of severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) infection in patients with pre‐existing primary immune thrombocytopenia (ITP) in Spain	15
Prognostic impact of FLT3‐ITD mutation on NPM1+ acute myeloid leukaemia patients and related molecular mechanisms	15
	15
High‐dose methotrexate pharmacokinetics and its impact on prognosis of paediatric acute lymphoblastic leukaemia patients: A population pharmacokinetic study	15
Issue Information	14
Erratum	14
The increasingly blurred line between induction, consolidation and maintenance in acute myeloid leukaemia	14
Baseline characteristics of Ghanaian children and adults enrolled in PIVOT, a randomised clinical trial of hydroxyurea in HbSC disease in sub‐Saharan Africa	14
Transfusion of red cells from donors with hereditary haemochromatosis improve haemoglobin increments in patients	14
Characterisation of children and adolescents with acute lymphoblastic leukaemia who presented without peripheral blood blasts at diagnosis	14
Cryoglobulin crystals deposited in a peripheral blood film and phagocytosed by neutrophils	14
Issue Information	14
	14
Issue Information	14
First‐line immunotherapy with anti‐PD‐1 antibody for extranodal NK/T‐cell lymphoma: A retrospective study	14
Effects of chemotherapy dose reductions in overweight patients with acute myeloid leukaemia: A Danish nationwide cohort study	14
How to discover the exceptional venetoclax responders in AML/MDS?	14
	14
The impact of B‐cell‐directed therapy on SARS‐CoV‐2 vaccine efficacy in chronic lymphocytic leukaemia	14
High on‐treatment platelet reactivity—an OPTIMAl solution, or a better solution?	14
Impact of pre‐eclampsia on renal outcome in sickle cell disease patients	14
The safety and acceptability of twice‐daily deferiprone for transfusional iron overload: A multicentre, open‐label, phase 2 study	14
Chimeric antigen receptor T‐cell therapy for mantle cell lymphoma with central nervous system involvement: Progress, but not perfect	14
Risk factors and survival analysis of human leukocyte antigen loss in relapsed acute myeloid leukaemia/myelodysplastic syndrome patients after allogeneic haematopoietic stem cell transplantation	14
External validation and calibration of the HoLISTIC Consortium's advanced‐stage Hodgkin lymphoma international prognostic index (A‐HIPI) in the Brazilian Hodgkin lymphoma registr	13
Characterisation of immune checkpoints in Richter syndrome identifies LAG3 as a potential therapeutic target	13
Human leukocyte antigen evolutionary divergence influences outcomes of paediatric patients and young adults affected by malignant disorders given allogeneic haematopoietic stem cell transplantation fr	13
Are the current guidelines for identification of myelodysplastic syndrome with germline predisposition strong enough?	13
Human papilloma virus (HPV)‐associated lesions in a post‐bone marrow transplant patient responding to HPV vaccination	13
Multiparameter flow cytometry in plasma cell disorders: when in doubt, go with the flow	13
Everyone is entitled to his or her own opinion but not to their own facts*	13
Immunophenotypic characterisation of acute myeloid leukaemia with UBTF tandem duplications	13
Expression of Concern: Effect of insulin‐like growth factor 1 on PHA‐stimulated cord blood mononuclear cell telomerase activity	13
Gaps in the diagnosis and management of iron overload in sickle cell disease: a ‘real‐world’ report from the GRNDaD registry	13
The usefulness of indium‐111 platelet scintigraphy beyond predicting efficacy of splenectomy	13
Cauda equina syndrome secondary to extramedullary erythropoiesis in a transfusion‐dependent thalassemia patient following treatment with luspatercept: A case report	13
Single‐cell profiling of ineffective erythropoiesis in a mouse model of β‐thalassaemia intermedia	13
Spurious thrombocytosis, red cell count and mean cell volume in a patient with thermal burns	13
The Russian invasion of Ukraine: Implications for haematologists	13
Absence of femur induced by haemophilic pseudotumour	13
FISH‐ing for answers: Can genomic arrays add to our understanding of disease biology in low‐risk chronic lymphocytic leukaemia?	13
Bortezomib, a promising alternative for patients with refractory or relapsed thrombotic thrombocytopenic purpura after rituximab treatment	13
Isocitrate dehydrogenase inhibitors as a bridge to allogeneic stem cell transplant in relapsed or refractory acute myeloid leukaemia	13
Fetal and neonatal alloimmune thrombocytopenia: No evidence of systemic inflammation as a modulator of disease severity. Could placental inflammation be key?	13
Effect of peptide‐binding motif on survival of HLA‐haploidentical transplantation with post‐transplant cyclophosphamide	13
Two novel families with RUNX1 variants indicate glycine 168 as a new mutational hotspot: Implications for FPD/AML diagnosis	13
Nicotinamide enhances Treg differentiation by promoting Foxp3 acetylation in immune thrombocytopenia	13
Inflammatory profile of lower risk myelodysplastic syndromes	13
Benefit of repeatedCOVID‐19 vaccination for patients with B‐cell malignancies	13
Screening for haemoglobin disorders: One size may not fit all	13
Updated revision of the British Society of Haematology guidelines for chronic lymphocytic leukaemia	13
The continuing global challenges of treating patients with beta‐thalassemia	13
Major haemorrhage: putting evidence into practice	12
Resolving sticky relationships between platelets and lymphocytes in COVID‐19: A role for checkpoint inhibitors?	12
The Menin story in acute myeloid leukaemia—The road to success	12
3q21 deletion affects GATA2 and is associated with myelodysplastic syndrome	12
Gene therapy with B‐cell maturation antigen/CD3 bispecific antibody encoding plasmid DNA for treating multiple myeloma	12
Myocardial iron intake following intravenous iron therapy with ferric carboxymaltose is sustained at 1 year despite recurrence of iron deficiency	12
Strategies to reduce relapse risk in patients undergoing allogeneic stem cell transplantation for acute myeloid leukaemia	12
Is there a role for eltrombopag drug levels in paediatric immune thrombocytopenia management?	12
Undetectable minimal residual disease is an independent prognostic factor in splenic marginal zone lymphoma	12
Generic romiplostim for children with persistent or chronic immune thrombocytopenia: Experience from a tertiary care centre in North India	12
Frequent health care utilisation and avascular necrosis are associated with cannabis use in adults with sickle cell disease	12
Erratum	12
Longitudinal evaluation of adverse events due to steroid use in primary immune thrombocytopenia: A population‐based study	12
Comparison of minimal residual disease measurement by multicolour flow cytometry and PCR for fusion gene transcripts in infants with acute lymphoblastic leukaemia with KMT2A gene rearrangements	12